Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRBUNASDAQ:CRDLNASDAQ:CVKDNASDAQ:EXOZ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRBUCaribou Biosciences$1.11-4.3%$0.93$0.66▼$3.00$103.24M2.441.37 million shs1.16 million shsCRDLCardiol Therapeutics$1.46+1.4%$1.14$0.77▼$2.63$120.67M1.03329,456 shs177,007 shsCVKDCadrenal Therapeutics$13.86-7.5%$15.32$5.70▼$22.90$27.26M1.140,967 shs19,706 shsEXOZExozymes$12.81-2.6%$12.68$8.50▼$23.99$107.19MN/A17,170 shs166 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRBUCaribou Biosciences-4.31%-11.90%+35.55%+9.90%-43.65%CRDLCardiol Therapeutics+1.39%+3.55%+31.53%+29.20%-50.84%CVKDCadrenal Therapeutics-7.54%-8.21%-1.98%-27.40%+1,385,999,900.00%EXOZExozymes-2.59%-4.69%-9.92%-16.55%+1,280,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRBUCaribou Biosciences3.4353 of 5 stars3.53.00.00.03.63.30.6CRDLCardiol Therapeutics2.236 of 5 stars3.72.00.00.03.10.00.6CVKDCadrenal Therapeutics3.2677 of 5 stars3.55.00.00.02.61.70.6EXOZExozymesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRBUCaribou Biosciences 3.00Buy$8.50665.77% UpsideCRDLCardiol Therapeutics 3.40Buy$8.67493.61% UpsideCVKDCadrenal Therapeutics 3.00Buy$32.00130.88% UpsideEXOZExozymes 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CVKD, CRBU, EXOZ, and CRDL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2025CRDLCardiol TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$9.005/16/2025CVKDCadrenal TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.004/28/2025CRBUCaribou BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $3.004/16/2025CRDLCardiol TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.004/7/2025CRDLCardiol TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.003/19/2025CRBUCaribou BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRBUCaribou Biosciences$9.92M10.41N/AN/A$4.17 per share0.27CRDLCardiol TherapeuticsN/AN/AN/AN/A$0.32 per shareN/ACVKDCadrenal TherapeuticsN/AN/AN/AN/A$8.86 per shareN/AEXOZExozymesN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRBUCaribou Biosciences-$102.07M-$1.62N/AN/AN/A-1,290.81%-45.46%-38.07%8/5/2025 (Estimated)CRDLCardiol Therapeutics-$20.84M-$0.34N/AN/AN/AN/A-194.40%-129.07%7/14/2025 (Estimated)CVKDCadrenal Therapeutics-$8.36M-$9.26N/AN/AN/AN/A-142.95%-118.40%8/6/2025 (Estimated)EXOZExozymesN/AN/A0.00∞N/AN/AN/AN/AN/ALatest CVKD, CRBU, EXOZ, and CRDL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025EXOZExozymesN/A-$0.22N/A-$0.22N/AN/A5/8/2025Q1 2025CRBUCaribou Biosciences-$0.43-$0.43N/A-$0.43$1.48 million$2.35 million5/8/2025Q1 2025CVKDCadrenal Therapeutics-$1.64-$2.09-$0.45-$2.09N/AN/A3/31/2025Q4 2024CRDLCardiol Therapeutics-$0.08-$0.07+$0.01-$0.07N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRBUCaribou BiosciencesN/AN/AN/AN/AN/ACRDLCardiol TherapeuticsN/AN/AN/AN/AN/ACVKDCadrenal TherapeuticsN/AN/AN/AN/AN/AEXOZExozymesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRBUCaribou BiosciencesN/A7.387.38CRDLCardiol Therapeutics0.012.492.49CVKDCadrenal TherapeuticsN/A3.693.69EXOZExozymesN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRBUCaribou Biosciences77.51%CRDLCardiol Therapeutics12.49%CVKDCadrenal Therapeutics7.92%EXOZExozymesN/AInsider OwnershipCompanyInsider OwnershipCRBUCaribou Biosciences8.28%CRDLCardiol Therapeutics5.25%CVKDCadrenal Therapeutics48.62%EXOZExozymesN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRBUCaribou Biosciences10093.01 million81.95 millionOptionableCRDLCardiol Therapeutics2082.65 million78.27 millionNot OptionableCVKDCadrenal Therapeutics41.97 million916,000Not OptionableEXOZExozymes298.37 millionN/AN/ACVKD, CRBU, EXOZ, and CRDL HeadlinesRecent News About These CompaniesExozymes (NASDAQ:EXOZ) Trading 3.9% Higher - Here's WhyJune 11 at 5:26 AM | marketbeat.comeXoZymes Highlights Scalable Biomanufacturing Platform and First Spinout, NCTx, on Grow Everything PodcastMay 16, 2025 | accessnewswire.comExozymes (NASDAQ:EXOZ) Issues Quarterly Earnings ResultsMay 14, 2025 | marketbeat.comeXoZymes Provides First Quarter 2025 and NCTx Subsidiary Update at 5PM EST TodayMay 12, 2025 | accessnewswire.comeXoZymes to Host First Quarter 2025 and Subsidiary NCTx Update on Monday May 12, 2025, at 5PM ESTMay 7, 2025 | accessnewswire.comeXoZymes Launches Subsidiary, NCTx, to Unlock a Promising Compound for Gut and Liver HealthMay 6, 2025 | accessnewswire.comBringing clarity and precision to the cell-free space by introducing exozymesApril 21, 2025 | globenewswire.comBioClick – an enzyme engineering game-changer, launched by eXoZymes and supported by a $300K NIH grantApril 10, 2025 | globenewswire.comeXoZymes Inc. Reports 2024 Progress and IPO SuccessApril 3, 2025 | tipranks.comeXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCOApril 2, 2025 | globenewswire.comeXoZymes Provides Fourth Quarter and Full Year 2024 UpdateApril 2, 2025 | globenewswire.comeXoZymes to Host Fourth Quarter and Full Year 2024 Results Conference Call on Wednesday April 2, 2025March 26, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCVKD, CRBU, EXOZ, and CRDL Company DescriptionsCaribou Biosciences NASDAQ:CRBU$1.11 -0.05 (-4.31%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$1.10 -0.01 (-0.90%) As of 06/13/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.Cardiol Therapeutics NASDAQ:CRDL$1.46 +0.02 (+1.39%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$1.44 -0.02 (-1.37%) As of 06/13/2025 07:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.Cadrenal Therapeutics NASDAQ:CVKD$13.86 -1.13 (-7.54%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$14.79 +0.93 (+6.71%) As of 06/13/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.Exozymes NASDAQ:EXOZ$12.81 -0.34 (-2.59%) As of 06/13/2025 11:09 AM EasterneXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
